U.S. FDA Authorizes Regeneron’s REGN-COV2 Monoclonal Antibody for Emergency Use Authorization Targeting Select COVID-19 Patients

The monoclonal antibody cocktail developed by Regeneron and made well-known by POTUS during his stay at Walter Reed Medical Center has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Initially called REGN-COV-2 and also...